Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Thompson Investment Management Inc.

Thompson Investment Management Inc. lessened its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 9.4% during the fourth quarter, Holdings Channel.com reports. The firm owned 8,830 shares of the company’s stock after selling 920 shares during the quarter. Thompson Investment Management Inc.’s holdings in Neurocrine Biosciences were worth $1,205,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in NBIX. Cetera Investment Advisers boosted its holdings in Neurocrine Biosciences by 7.9% in the 2nd quarter. Cetera Investment Advisers now owns 7,112 shares of the company’s stock valued at $979,000 after purchasing an additional 519 shares in the last quarter. Sanctuary Advisors LLC purchased a new stake in shares of Neurocrine Biosciences during the 2nd quarter worth approximately $510,000. GAMMA Investing LLC boosted its stake in shares of Neurocrine Biosciences by 11.9% during the 3rd quarter. GAMMA Investing LLC now owns 1,738 shares of the company’s stock worth $200,000 after acquiring an additional 185 shares in the last quarter. CWM LLC boosted its stake in shares of Neurocrine Biosciences by 15.1% during the 3rd quarter. CWM LLC now owns 7,884 shares of the company’s stock worth $908,000 after acquiring an additional 1,035 shares in the last quarter. Finally, Perpetual Ltd boosted its stake in shares of Neurocrine Biosciences by 96.6% during the 3rd quarter. Perpetual Ltd now owns 12,560 shares of the company’s stock worth $1,447,000 after acquiring an additional 6,170 shares in the last quarter. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Stock Down 18.5 %

NBIX stock opened at $122.62 on Friday. The company has a market cap of $12.42 billion, a price-to-earnings ratio of 37.27 and a beta of 0.33. The business has a fifty day simple moving average of $138.81 and a 200-day simple moving average of $131.62. Neurocrine Biosciences, Inc. has a 52 week low of $110.95 and a 52 week high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Thursday, February 6th. The company reported $1.00 EPS for the quarter, missing analysts’ consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.45% and a net margin of 14.49%. As a group, analysts expect that Neurocrine Biosciences, Inc. will post 6.53 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Neurocrine Biosciences news, insider Jude Onyia sold 2,331 shares of the company’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $126.29, for a total value of $294,381.99. Following the completion of the transaction, the insider now directly owns 15,449 shares of the company’s stock, valued at $1,951,054.21. This represents a 13.11 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Ingrid Delaet sold 1,091 shares of the company’s stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $135.00, for a total transaction of $147,285.00. Following the completion of the transaction, the insider now directly owns 2,507 shares of the company’s stock, valued at approximately $338,445. The trade was a 30.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 222,693 shares of company stock valued at $32,718,279. Company insiders own 4.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Canaccord Genuity Group decreased their price target on Neurocrine Biosciences from $172.00 to $163.00 and set a “buy” rating on the stock in a research note on Friday. BMO Capital Markets decreased their price target on Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating on the stock in a research note on Thursday, October 17th. Bank of America reduced their target price on Neurocrine Biosciences from $184.00 to $179.00 and set a “buy” rating on the stock in a research note on Friday. William Blair reaffirmed an “outperform” rating on shares of Neurocrine Biosciences in a research note on Friday. Finally, Morgan Stanley upped their target price on Neurocrine Biosciences from $170.00 to $185.00 and gave the company an “overweight” rating in a research note on Tuesday, February 4th. Four research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $169.20.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.